Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: A Swiss perspective (ROSSO study No. 11)

Swiss Medical Weekly

Volumn 137, Issue 39-40, 2007, Pages 545-550

  Weher, Christian ^a   Schneider, Berthold ^b   Lodwig, Volker ^a   Holm, Majbrit V ^c   Neeser, Kurt ^a  

^a Institute for Medical Informatics and Biostatistics   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cost; Cost of illness; Diabetes type 2; Self monitoring of blood glucose; Switzerland

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DRUG COST; FOOT AMPUTATION; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; REVIEW; SELF MONITORING; STROKE; SWITZERLAND;

EID: 35348822400     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health. 2004;14:3-9.
2. Wing RR, Epstein LH, Nowalk MP, Scott N, Koeske R, Hagg S. Does self-monitoring of blood glucose levels improve dietary compliance for obese patients with type II diabetes? Am J Med. 1986;81:830-6.
3. Fontbonne A, Billault B, Acosta M, Percheron C, Varenne P, Besse A, et al. Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial. Diabete Metab. 1989;15:255-60.
4. Rutten G, van Eijk J, de Nobel E, Beek M, van der Velden H. Feasibility and effects of a diabetes type II protocol with blood glucose self-monitoring in general practice. Fam Pract. 1990;7:273-8.
5. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol. 1994;31:215-9.
6. Brown SA, Garcia AA, Kouzekanani K, Hanis CL. Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative. Diabetes Care. 2002;25:259-68.
7. Schwedes U, Siebolds M, Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care. 2002;25:1928-32.
8. Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab. 2003;29:587-94.
9. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med. 2005;118:422-5.
10. Sarol JN, Nicodemus NA, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin. 2005;21:173-84.
11. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev. 2005;CD005060.
12. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22:671-81.
13. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, KoIb H, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49:271-8.
14. Weber C, Neeser K, Wenzel H, Schneider B. Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No. 2). J Med Econ. 2006;9:45-53.
15. Davidson MB. Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care. 2005;28:1531-3.
16. Ipp E, Aquino RL, Christenson P. Point: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: The sanguine approach. Diabetes Care. 2005;28:1528-30.
17. Aurbach A, Russ W, Battegay E, Bucher HC, Brecht JG, Schadlich PK, et al. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective. Swiss Med Wkly. 2004;134:399-405.
18. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics. 2003;21:651-9.
19. Holler D, Claes C, der Schulenburg JM. Treatment costs and quality of life of patients with peripheral arterial occlusive disease - the German perspective. Vasa. 2004;33:145-53.
20. Weber C, Neeser K, Wenzel H, Schneider B. Cost of diabetes mellitus type 2 and self measurement of blood glucose in Germany: A health insurance perspective. Value Health. 2005;8:A158.
21. Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health. 2001;4:16-31.
22. Frei A, Lindgren P, Meier B. Cost-effectiveness of clopidogrel in patients with acute coronary syndrome in Switzerland. Kardiovask Med. 2004;7:174-80.
23. Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care. 2002;11:70-4.
24. Stockl K, Vanderplas A, Tafesse E, Chang E. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care. 2004;27:2129-34.
25. Gozzoli V, Palmer AJ, Brandt A, Spinas GA. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Swiss Med Wkly. 2001;131:303-10.
26. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol. 2001;16:218-22.
27. Zentralstelle für Medizinaltarife UVG http://www.zmt.ch/it/ ambulante_tarife_spitalleistungs-katalog.pdf. 2006. (last visted: 2006-08-31)
28. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia. 2000;43:13-26.
29. Sandoz MS, Ess SM, Keusch GW, Schwenkglenks M, Szucs TD. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004;134:448-58.
30. Rathmann W, Haastert B, Giani G. Drug prescriptions and costs in diabetic polyneuropathy. Dtsch Med Wochenschr. 1999;124:681-6.
31. http://www.galinfo.net. 2006. (last visited: 2006-08-31)
32. http://www.kompendium.ch. 2006 (last visited: 2006-08-31)